Methuselah Foundation and the Mprize
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Mouse lifespan-extension results underlying the Mprize are legitimate, published animal-model findings, but translation to human healthspan or lifespan extension has not been demonstrated, and the Foundation's role is as an incentive-prize and early-stage funding intermediary rather than a clinical evidence generator.
Reference only. Not medical advice.
The Methuselah Foundation is a US 501(c)(3) nonprofit, based in Springfield, Virginia and led by co-founder and CEO David Gobel, created to accelerate research into extending healthy human lifespan. Its best-known initiative, the Mprize, is a scientific incentive prize structured in two parts: a Longevity Prize for the research team that produces the longest-lived laboratory mouse, and a Rejuvenation Prize for interventions that most effectively extend remaining lifespan when started in middle-aged mice, a design intended to reward genuine rejuvenation rather than simple slow-aging genetics. Early prize funds grew from modest seed money toward a publicized goal of one million dollars through donations, drawing mainstream press attention as an unconventional way to fund aging research through public incentive rather than only traditional grants. Early winners illustrate the Mprize's two tracks. Andrzej Bartke's laboratory at Southern Illinois University won longevity recognition for a mouse that lived to roughly 1,819 days through a combination of genetic growth-hormone suppression and dietary intervention, described in press coverage as equivalent to an unusually long human lifespan. Stephen Spindler's group at the University of California, Riverside won early rejuvenation-track recognition for work on caloric restriction and late-life dietary intervention. Since these early contests, the Foundation has broadened its focus beyond the mouse prize toward direct investment: it operates the Methuselah Fund, an early-stage venture vehicle that has backed regenerative-medicine and tissue-engineering startups, funds organ preservation and 3D bioprinting research (including a longstanding challenge for engineering a vascularized artificial organ), and has run programs in partnership with NASA on space-relevant biomedical research. Major historical donors have included PayPal co-founder and investor Peter Thiel, who contributed 3.5 million dollars in 2006, and later contributions from the Pineapple Fund and Ethereum co-founder Vitalik Buterin. The Methuselah Foundation is widely credited within the aging-research community, alongside SENS, with helping move longevity science from a fringe pursuit associated with anti-aging marketing toward a field with growing institutional, academic, and now substantial private-investment legitimacy, though the Foundation itself remains a nonprofit intermediary and incentive-prize sponsor rather than a direct drug developer, and the practical translation of mouse-lifespan extension techniques into approved human therapies remains at an early, unproven stage.
The Methuselah Foundation is a US 501(c)(3) nonprofit, based in Springfield, Virginia and led by co-founder and CEO David Gobel, created to accelerate research into extending healthy human lifespan.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Incorporated in 2001 by David Gobel as the Performance Prize Society, the organization was rebranded the Methuselah Foundation in 2003, named after the biblical figure associated with extreme age, with biogerontologist Aubrey de Grey joining as a co-founder and chairman. Its flagship program, the Mprize (originally the Methuselah Mouse Prize), was launched in 2003 as an incentive prize for laboratory results extending mouse lifespan and healthspan. From 2003 to 2009 the Foundation also incubated the Strategies for Engineered Negligible Senescence (SENS) research program before SENS spun off as the independent SENS Research Foundation in 2009.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Methuselah Foundation and the Mprize. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.